Pfizer hits deal to buy GBT for $5.4 billion - report

Monday, 08. August 2022 12:38

Pfizer Inc. reached a deal to buy Global Blood Therapeutics Inc. for $5.4 billion or $68.50 a share in cash, according to a report published by the Wall Street Journal on Monday.

Confirming earlier reports, sources familiar with the agreement told the outlet that the official announcement will likely be made later today.

Global Blood Therapeutics is known for having one of the rare treatments for sickle-cell disease, which Pfizer also tried making but was unsuccessful. Next to the San Francisco company, Novartis AG also sells a treatment for pain crises in sickle-cell patients.

Related Links: Global Blood Therapeutics Inc.Pfizer Inc.
Author:
Baha Breaking News (BBN) / ND